Comparative Pharmacology
Head-to-head clinical analysis: MYCHEL versus NEOBIOTIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYCHEL versus NEOBIOTIC.
MYCHEL vs NEOBIOTIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mychel is a topical antifungal agent that inhibits ergosterol synthesis by binding to fungal cytochrome P450 14α-demethylase, disrupting fungal cell membrane integrity.
NEOBIOTIC is a combination antibiotic product containing neomycin (aminoglycoside) and bacitracin (polypeptide antibiotic). Neomycin binds to the 30S ribosomal subunit of bacteria, causing misreading of mRNA and inhibiting protein synthesis. Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier that transports peptidoglycan subunits.
Adults: 200 mg orally twice daily for 14 days.
1 g intravenously every 12 hours.
None Documented
None Documented
Terminal half-life: 8.5-12 hours (mean 10.2 h) in normal renal function; prolonged to 18-30 h in severe renal impairment (CrCl <30 mL/min)
3.5–4.5 hours (terminal) in adults with normal renal function; prolonged to 12–18 hours in severe renal impairment (CrCl <30 mL/min).
Renal: ~70% unchanged; fecal: ~15% as metabolites; biliary: ~10%
Renal: 30–40% unchanged; fecal: 50–60% via biliary elimination; minimal hepatic metabolism.
Category C
Category C
Antibiotic
Antibiotic